Kiadis Pharma announces new data on ex-vivo FC21 expanded NK-cell therapy in 13 patients with relapsed/refractory acute myeloid leukemia will be presented at the European Society for Blood and Marrow Transplantation Annual Meeting*

EBMT Abstract #A-1137-0005-00784

Amsterdam, The Netherlands, March 10, 2020 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company, today announces an abstract showcasing the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML) has been accepted for an oral presentation at the 46^th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT). Lucia Mariano da Rocha Silla, MD, PhD, will present the data at EBMT, which is taking place 30 August – 2 September in Madrid, Spain. These data are from a Phase I study conducted by Dr. Silla at Hospital de Clínicas de Porto Alegre (HCPA) in Brazil. In this study, sponsored by the Brazilian Agencies for Research development, the adoptive transfer of haploidentical expanded NK cells to restore NK cell numbers and anti-leukemia function in patients with relapsed/refractory AML was investigated.

Presentation Details

Title: Phase 1 Study of Adoptive Transfer of Haploidentical Expanded NK Cells

Presenter: Lucia Mariano da Rocha Silla, MD, PhD

Abstract #: #A-1137-0005-00784 (https://www.professionalabstracts.com/ebmt2020/iPlanner/#/presentation/817)

Session Name: OS6 session 6 - Cellular therapy other than CARs

*EBMT has postponed its 46th Annual Meeting from March 2020 to 30 August to 2 September 2020.

Kiadis Pharma Contact
Maryann Cimino, Manager, Corporate Affairs
Tel: +1 (617) 710-7305
m.cimino@kiadis.com

About Kiadis Pharma’s K-NK-Cell Therapies
Kiadis Pharma’s NK-cell programs consist of off-the-shelf and haplo donor cell therapy products for the treatment of liquid and solid tumors as adjunctive and stand-alone therapies. 

The Company’s NK-cell PM21 particle technology enables improved ex vivo expansion and activation of anti-cancer cytotoxic NK-cells supporting multiple high-dose infusions. Kiadis Pharma’s proprietary off-the-shelf NK-cell platform is based on NK-cells from unique universal donors. The Kiadis Pharma off-the-shelf K-NK platform can make NK-cell therapy product rapidly and economically available for a broad patient population across a potentially wide range of indications.

Kiadis Pharma is clinically developing K-NK003 for the treatment of relapse/refractory acute myeloid leukemia. The Company is also developing K-NK002, which is administered as an adjunctive immunotherapeutic on top of HSCT and provides functional, mature and potent NK-cells from a haploidentical family member. In addition, the Company has pre-clinical programs evaluating NK-cell therapy for the treatment of solid tumors. 

About Kiadis Pharma

Founded in 1997, Kiadis Pharma is building a fully integrated biopharmaceutical company committed to developing innovative therapies for patients with life-threatening diseases. With headquarters in Amsterdam, the Netherlands, and offices and activities across the United States, Kiadis Pharma is reimagining medicine by leveraging the natural strengths of humanity and our collective immune system to source the best cells for life.

Kiadis Pharma is listed on the regulated market of Euronext Amsterdam and Euronext Brussels since July 2, 2015, under the symbol KDS. Learn more at kiadis.com.

Forward Looking Statements
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect Kiadis Pharma or, as appropriate, Kiadis Pharma officers’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of known and unknown risks, uncertainties and assumptions that could cause actual results, performance, achievements or events to differ materially from those expressed, anticipated or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, regulation, competition and technology, can cause actual events, performance, achievements or results to differ significantly from any anticipated or implied development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, Kiadis Pharma expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or projections, or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither Kiadis Pharma nor its advisers or representatives nor any of its subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the anticipated or implied developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.